Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: A case report

How Wen Ko; Ying Huang Tsai; Chih Teng Yu; Chun Yao Huang; Chih Hung Chen

Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: A case report

How Wen Ko, Ying Huang Tsai, Chih Teng Yu, Chun Yao Huang, Chih Hung Chen^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

2 Scopus citations

Abstract

Hyperamylasemia in patients with bronchogenic carcinoma has been reported rarely. Gefitinib, an oral tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) signaling, has shown activity for treating patients with refractory advanced non-small cell lung cancer (NSCLC). This report describes a case of lung adenocarcinoma coexisting with hyperamylasemia in a 67-year-old man. Abdominal computed tomograhy and ultrasonography demonstrated a normal pancreas. A mutational analysis of the EGFR gene indicated an in-frame deletion at exon 19. He underwent treatment with gefitinib. Chest radiography follow-up showed a partial response and the amylase level also decreased to normal. We suggest that treatment with gefitinib is an effective therapeutic option for this rare patient subset.

Original language	English
Pages (from-to)	606-611
Number of pages	6
Journal	Chang Gung Medical Journal
Volume	31
Issue number	6
State	Published - 11 2008

Keywords

Amylase
EGFR mutation
Epidermal growth factor receptor (EGFR)
Gefitinib
Non-small cell lung cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{f1e8792f63554df1898f6f32e390f992,

title = "Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: A case report",

abstract = "Hyperamylasemia in patients with bronchogenic carcinoma has been reported rarely. Gefitinib, an oral tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) signaling, has shown activity for treating patients with refractory advanced non-small cell lung cancer (NSCLC). This report describes a case of lung adenocarcinoma coexisting with hyperamylasemia in a 67-year-old man. Abdominal computed tomograhy and ultrasonography demonstrated a normal pancreas. A mutational analysis of the EGFR gene indicated an in-frame deletion at exon 19. He underwent treatment with gefitinib. Chest radiography follow-up showed a partial response and the amylase level also decreased to normal. We suggest that treatment with gefitinib is an effective therapeutic option for this rare patient subset.",

keywords = "Amylase, EGFR mutation, Epidermal growth factor receptor (EGFR), Gefitinib, Non-small cell lung cancer",

author = "Ko, {How Wen} and Tsai, {Ying Huang} and Yu, {Chih Teng} and Huang, {Chun Yao} and Chen, {Chih Hung}",

year = "2008",

month = nov,

language = "英语",

volume = "31",

pages = "606--611",

journal = "Chang Gung Medical Journal",

issn = "0255-8270",

number = "6",

}

TY - JOUR

T1 - Good response to gefitinib for lung adenocarcinoma with hyperamylasemia

T2 - A case report

AU - Ko, How Wen

AU - Tsai, Ying Huang

AU - Yu, Chih Teng

AU - Huang, Chun Yao

AU - Chen, Chih Hung

PY - 2008/11

Y1 - 2008/11

N2 - Hyperamylasemia in patients with bronchogenic carcinoma has been reported rarely. Gefitinib, an oral tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) signaling, has shown activity for treating patients with refractory advanced non-small cell lung cancer (NSCLC). This report describes a case of lung adenocarcinoma coexisting with hyperamylasemia in a 67-year-old man. Abdominal computed tomograhy and ultrasonography demonstrated a normal pancreas. A mutational analysis of the EGFR gene indicated an in-frame deletion at exon 19. He underwent treatment with gefitinib. Chest radiography follow-up showed a partial response and the amylase level also decreased to normal. We suggest that treatment with gefitinib is an effective therapeutic option for this rare patient subset.

AB - Hyperamylasemia in patients with bronchogenic carcinoma has been reported rarely. Gefitinib, an oral tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) signaling, has shown activity for treating patients with refractory advanced non-small cell lung cancer (NSCLC). This report describes a case of lung adenocarcinoma coexisting with hyperamylasemia in a 67-year-old man. Abdominal computed tomograhy and ultrasonography demonstrated a normal pancreas. A mutational analysis of the EGFR gene indicated an in-frame deletion at exon 19. He underwent treatment with gefitinib. Chest radiography follow-up showed a partial response and the amylase level also decreased to normal. We suggest that treatment with gefitinib is an effective therapeutic option for this rare patient subset.

KW - Amylase

KW - EGFR mutation

KW - Epidermal growth factor receptor (EGFR)

KW - Gefitinib

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=58149102343&partnerID=8YFLogxK

M3 - 文章

C2 - 19241901

AN - SCOPUS:58149102343

SN - 0255-8270

VL - 31

SP - 606

EP - 611

JO - Chang Gung Medical Journal

JF - Chang Gung Medical Journal

IS - 6

ER -

Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: A case report

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this